Status:

COMPLETED

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial

Lead Sponsor:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Gastroparesis

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

The principal objective of this multicenter, randomized, placebo-controlled trial is to evaluate whether 4 weeks of treatment with aprepitant will improve nausea as compared with placebo in patients w...

Detailed Description

APRON is a multicenter, randomized, double-masked, placebo controlled trial of 4 weeks of treatment with aprepitant or placebo for patients with symptoms of gastroparesis and related disorders. Screen...

Eligibility Criteria

Inclusion

  • Age 18 years or older at registration
  • Gastric emptying scintigraphy within 2 years of registration
  • Normal upper endoscopy or upper GI series within 2 years of registration
  • Symptoms of chronic nausea or vomiting compatible with gastroparesis or other functional gastric disorder for at least 6 months (does not have to be contiguous) prior to registration with Gastroparesis Cardinal Symptom Index (GCSI) score of greater than or equal to 21
  • Significant nausea defined with a visual analog scale (VAS) score of greater than or equal to 25 mm on a 0 to 100 mm scale

Exclusion

  • Another active disorder which could explain symptoms in the opinion of the investigator
  • Use of narcotics more than 3 days per week
  • Significant hepatic injury as defined by significant alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevations of greater than 2x the upper limit of normal (ULN) or a Child-Pugh score of 10 or greater
  • Contraindications to aprepitant such as hypersensitivity or allergy
  • Concurrent use of warfarin, pimozide, terfenadine, astemizole, or cisapride
  • Pregnancy or nursing
  • Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study
  • Failure to give informed consent

Key Trial Info

Start Date :

April 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2015

Estimated Enrollment :

126 Patients enrolled

Trial Details

Trial ID

NCT01149369

Start Date

April 1 2013

End Date

September 1 2015

Last Update

May 8 2019

Active Locations (8)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (8 locations)

1

California Pacific Medical Center

San Francisco, California, United States, 94115

2

Stanford University

Stanford, California, United States, 94305-5187

3

University of Louisville

Louisville, Kentucky, United States, 40202

4

Johns Hopkins Bayview Medical Center

Baltimore, Maryland, United States, 21224

Aprepitant for the Relief of Nausea in Patients With Chronic Nausea and Vomiting of Presumed Gastric Origin Trial | DecenTrialz